## Review setup
- **Input scope** Abstract only
- **Assessment boundary** The abstract describes a methods protocol for computational network analysis of transcriptional programs in cancer, with no results, figures, or validation data provided
- **Shared manuscript claim summary** The authors present a reproducible network-based workflow for reconstructing and analyzing transcriptional regulatory programs across human cancer types, using publicly available expression datasets, random forest classification, and the CellNet platform, with procedures for evaluating classifier performance, quantifying network influence scores, integrating transcription factor target interaction resources, performing functional enrichment analyses, and comparing cancer-specific networks with normal tissue profiles to identify candidate drivers and prognostic biomarkers
- **Visible evidence base** Abstract text only; no methods details, figures, tables, or validation results are available
- **Missing materials affecting confidence** Full methods text, all figures and tables, validation datasets, code availability information, and any performance metrics or benchmarking results

## Reviewer
- **Overall assessment** The abstract describes a potentially useful methods protocol for cancer transcriptomic network analysis, but the provided material is insufficient to evaluate the technical soundness, novelty, or practical utility of the workflow. The claims are broad and largely unverifiable from the abstract alone. The protocol appears to combine existing tools (CellNet, random forest, GEO data) in a structured pipeline, but whether this constitutes a meaningful advance over prior methods cannot be assessed without full methodological detail and validation.
- **Who would be interested in the results, and why** Computational biologists and bioinformaticians working on gene regulatory network reconstruction, cancer genomics researchers seeking reproducible workflows for analyzing tumor transcriptional states, and method developers interested in applying machine learning approaches to public expression data. The protocol format suggests a target audience of researchers seeking practical guidance for implementing such analyses.
- **Major strengths** The workflow emphasizes reproducibility and use of publicly available data, which is commendable. The integration of multiple analytical steps (preprocessing, classification, network reconstruction, enrichment analysis, comparative analysis) into a single framework could provide practical value. The focus on cancer type-specific networks and comparison with normal tissue is biologically relevant.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
  - R1-m4
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality cannot be assessed from the abstract alone; the combination of existing tools may be incremental rather than novel. Scientific importance is potentially moderate, as reproducible cancer network analysis workflows are useful, but the abstract does not demonstrate biological insights or methodological advances. Interdisciplinary readership is limited to computational biology and cancer genomics specialists. Technical soundness is unverifiable without methods details and validation. Readability for nonspecialists is adequate for an abstract but the protocol itself would require clear documentation to be accessible.
- **Recommendation posture** Currently not established from the provided evidence. The abstract alone does not provide sufficient material to assess whether the protocol is technically sound, novel, or practically useful. A full manuscript with methods details, validation, and code availability would be required for a supportive assessment.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The workflow is described as "reproducible" and provides "detailed guidance" for implementing the described procedures
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract claims the workflow is reproducible and provides detailed guidance, but no methodological details, parameter choices, or implementation specifics are provided. The reproducibility of a computational workflow depends critically on exact software versions, parameter settings, and data preprocessing decisions, none of which are visible.
- **Why it matters** Reproducibility is a core claim of the protocol. Without evidence of detailed methods, code availability, or versioned dependencies, the central promise of the workflow cannot be evaluated or trusted by potential users.
- **Resolution test** Provide full methods text with specific software versions, parameter values, and a link to publicly available code and documentation. Include a demonstration of reproducibility, such as running the workflow on a test dataset with consistent outputs.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Validation and performance
- **Claim pointer** The abstract implies the workflow is effective for "defining cancer type-specific transcriptional states" and "systematically interrogating regulatory mechanisms"
- **Evidence pointer** Abstract only; location not provided
- **Concern** No validation results, benchmarking, or performance metrics are presented. The abstract does not show that the workflow produces accurate classifications, meaningful network reconstructions, or biologically valid driver predictions. Without validation on known datasets or comparison to existing methods, the effectiveness of the workflow is unsubstantiated.
- **Why it matters** A methods protocol must demonstrate that it works as intended. Unvalidated claims of utility could mislead researchers who adopt the workflow, and the scientific community requires evidence of performance before accepting a new method.
- **Resolution test** Include validation results such as classifier accuracy on held-out datasets, network reconstruction quality compared to known regulatory interactions, and biological validation of predicted drivers or biomarkers using independent data.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Novelty and contribution
- **Claim pointer** The abstract presents the workflow as a "scalable computational framework" without positioning it relative to existing methods
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract does not state what is new about this workflow compared to existing approaches. CellNet is an established platform, random forest classification is standard, and GEO data curation is routine. The abstract does not clarify whether the contribution is a novel integration, an improved implementation, or a new analytical step.
- **Why it matters** For a methods paper, the contribution must be clearly defined. Without a statement of novelty or a comparison to prior work, the scientific value of the protocol is unclear and the case for publication is weak.
- **Resolution test** Add a clear statement of novelty in the abstract and full text, including a comparison to existing workflows and a discussion of what the new approach enables that prior methods do not.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Abstract; location not provided
- **Issue** The phrase "integrating transcription factor, target interaction resources" is grammatically awkward and ambiguous. It is unclear whether this refers to integrating transcription factor target interaction databases or integrating transcription factors with target interaction resources.
- **Required correction** Rephrase for clarity, for example "integrating transcription factor target interaction databases" or "integrating transcription factor and target interaction resources."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Scope
- **Affected element** Data scope
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract specifies "microarray data from the Gene Expression Omnibus" but does not mention RNA-seq data, which is now the dominant transcriptomic profiling method. This may limit the applicability of the workflow.
- **Required correction** Clarify whether the workflow is limited to microarray data or can be adapted to RNA-seq data, and if so, describe the necessary modifications.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Prognostic biomarker claim
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract claims the workflow can identify "potential prognostic biomarkers" but does not describe how prognostic value is assessed or validated. This claim appears to extend beyond the described analytical steps.
- **Required correction** Either remove the prognostic biomarker claim or briefly describe the survival analysis or clinical correlation steps that would support it.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Accessibility
- **Affected element** Code and data availability
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract emphasizes reproducibility but does not mention code availability, which is essential for a computational methods protocol.
- **Required correction** State where the code and any example datasets can be accessed, such as a repository link or supplementary materials.

## Risk / unsupported claims
- The claim of reproducibility is unsupported without code availability and detailed methods
- The claim of effectiveness for defining cancer type-specific transcriptional states is unsupported without validation results
- The claim of identifying candidate drivers of malignant cell identity is unsupported without biological validation
- The claim of identifying potential prognostic biomarkers is unsupported and appears to exceed the described analytical scope
- The overall utility and scalability of the workflow cannot be assessed from the abstract alone